TAIPEI and SAN DIEGO, Dec. 23, 2025 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage companies focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today outlined continued progress across its AI-enabled drug…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
